Amundi Trims Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• Amundi sharply reduced its Halozyme stake by 84.9% in the second quarter, selling 103,250 shares and retaining 18,349 shares valued at approximately $1.44 million. Institutional investors and hedge funds collectively own 97.79% of the company.
• Halozyme reported strong quarterly results, with EPS of $2.28 versus the $1.79 consensus and revenue of $481 million, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Analyst sentiment remains favorable, with nine Buy ratings and a “Moderate Buy” consensus, although the average price target of $91.20 is below the stock’s reported $107.20 price. Insiders sold 72,478 shares worth $7.37 million over the past 90 days.

Amundi cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 84.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 18,349 shares of the biopharmaceutical company's stock after selling 103,250 shares during the period. Amundi's holdings in Halozyme Therapeutics were worth $1,436,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its position in Halozyme Therapeutics by 7,724.2% in the 2nd quarter. California State Teachers Retirement System now owns 10,668,044 shares of the biopharmaceutical company's stock valued at $834,988,000 after buying an additional 10,531,698 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at approximately $214,504,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics during the second quarter worth $196,540,000. Norges Bank purchased a new position in Halozyme Therapeutics during the 4th quarter valued at about $128,201,000. Finally, Jupiter Topco LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $105,570,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

HALO opened at $107.20 on Monday. The business's 50 day moving average is $93.73 and its 200-day moving average is $77.01. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a market cap of $12.17 billion, a PE ratio of 32.00, a price-to-earnings-growth ratio of 0.41 and a beta of 0.88. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $111.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, analysts predict that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently commented on HALO shares. Citizens Jmp increased their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research note on Friday, August 7th. Benchmark restated a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. HC Wainwright reaffirmed a "buy" rating and set a $115.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, September 2nd. UBS Group reaffirmed a "buy" rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $91.20.

Insiders Place Their Bets

In other news, Director Bernadette Connaughton sold 1,626 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director owned 40,418 shares in the company, valued at $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $107.24, for a total transaction of $2,144,800.00. Following the transaction, the chief executive officer owned 767,780 shares of the company's stock, valued at approximately $82,336,727.20. This trade represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 72,478 shares of company stock worth $7,370,004 over the last ninety days. Company insiders own 2.50% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company's primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.